United Capital Financial Advisers, LLC Astrazeneca PLC Transaction History

United Capital Financial Advisers, LLC

$19.9 Billion
Q3 2024

A detailed history of United Capital Financial Advisers, LLC transactions in Astrazeneca PLC stock. As of the latest transaction made, United Capital Financial Advisers, LLC holds 49,270 shares of AZN stock, worth $3.22 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

49,270

Previous 49,258 0.02%

Holding current value

$3.22 Million

Previous $3.84 Million 0.05%

% of portfolio

0.02%

Previous 0.03%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$76.67 - $87.62 $920 - $1,051	12 Added 0.02%	49,270 $3.84 Million
Q2 2024 Aug 14, 2024	SELL	$66.81 - $80.83 $8,952 - $10,831	-134 Reduced 0.27%	49,258 $3.84 Million
Q1 2024 May 15, 2024	SELL	$61.03 - $69.57 $172,775 - $196,952	-2,831 Reduced 5.42%	49,392 $3.35 Million
Q4 2023 Feb 14, 2024	SELL	$61.89 - $69.28 $1.1 Million - $1.23 Million	-17,749 Reduced 25.37%	52,223 $3.52 Million
Q3 2023 Nov 14, 2023	BUY	$64.85 - $71.7 $354,924 - $392,414	5,473 Added 8.49%	69,972 $4.74 Million
Q2 2023 Aug 14, 2023	BUY	$69.91 - $75.81 $901,139 - $977,190	12,890 Added 24.98%	64,499 $4.62 Million
Q1 2023 Aug 14, 2023	SELL	$63.15 - $71.6 $814,003 - $922,923	-12,890 Reduced 19.98%	51,609 $3.58 Million
Q1 2023 May 15, 2023	BUY	$63.15 - $71.6 $1.08 Million - $1.22 Million	17,089 Added 49.5%	51,609 $3.58 Million
Q4 2022 Feb 14, 2023	SELL	$54.21 - $70.44 $282,054 - $366,499	-5,203 Reduced 13.1%	34,520 $2.34 Million
Q3 2022 Nov 14, 2022	SELL	$53.02 - $135.75 $174,966 - $447,975	-3,300 Reduced 7.67%	39,723 $2.18 Million
Q2 2022 Aug 11, 2022	SELL	$59.26 - $71.14 $410,553 - $492,857	-6,928 Reduced 13.87%	43,023 $2.84 Million
Q1 2022 May 16, 2022	SELL	$55.72 - $67.12 $50,705 - $61,079	-910 Reduced 1.79%	49,951 $3.31 Million
Q4 2021 Feb 14, 2022	BUY	$54.02 - $63.83 $383,163 - $452,746	7,093 Added 16.21%	50,861 $2.96 Million
Q3 2021 Nov 15, 2021	BUY	$55.56 - $60.79 $400,643 - $438,356	7,211 Added 19.73%	43,768 $2.63 Million
Q2 2021 Aug 13, 2021	SELL	$48.42 - $60.18 $16,365 - $20,340	-338 Reduced 0.92%	36,557 $2.19 Million
Q1 2021 May 14, 2021	SELL	$47.16 - $54.44 $102,101 - $117,862	-2,165 Reduced 5.54%	36,895 $1.83 Million
Q4 2020 Feb 17, 2021	BUY	$48.52 - $58.02 $1.53 Million - $1.84 Million	31,636 Added 426.13%	39,060 $1.95 Million
Q3 2020 Nov 13, 2020	SELL	$53.07 - $61.1 $179,217 - $206,334	-3,377 Reduced 31.27%	7,424 $407,000
Q2 2020 Aug 13, 2020	SELL	$43.1 - $55.31 $24,049 - $30,862	-558 Reduced 4.91%	10,801 $571,000
Q1 2020 May 15, 2020	SELL	$37.79 - $51.33 $824,955 - $1.12 Million	-21,830 Reduced 65.77%	11,359 $507,000
Q4 2019 Feb 14, 2020	BUY	$42.46 - $50.46 $831,833 - $988,561	19,591 Added 144.07%	33,189 $1.66 Million
Q3 2019 Nov 14, 2019	SELL	$40.12 - $45.47 $761,878 - $863,475	-18,990 Reduced 58.27%	13,598 $606,000
Q2 2019 Aug 13, 2019	BUY	$37.28 - $41.68 $154,376 - $172,596	4,141 Added 14.56%	32,588 $1.35 Million
Q1 2019 May 14, 2019	SELL	$35.49 - $43.02 $70,376 - $85,308	-1,983 Reduced 6.52%	28,447 $1.15 Million
Q4 2018 Feb 14, 2019	BUY	$36.86 - $41.49 $129,562 - $145,837	3,515 Added 13.06%	30,430 $1.16 Million
Q3 2018 Nov 14, 2018	BUY	$34.76 - $39.72 $130,002 - $148,552	3,740 Added 16.14%	26,915 $1.07 Million
Q2 2018 Aug 14, 2018	BUY	$34.55 - $37.05 $181,732 - $194,882	5,260 Added 29.36%	23,175 $814,000
Q1 2018 May 15, 2018	BUY	$32.97 - $36.63 $156,211 - $173,552	4,738 Added 35.96%	17,915 $627,000
Q4 2017 Feb 13, 2018	BUY	$32.09 - $34.78 $77,304 - $83,785	2,409 Added 22.37%	13,177 $449,000
Q3 2017 Nov 14, 2017	BUY	$28.96 - $34.0 $24,297 - $28,526	839 Added 8.45%	10,768 $365,000
Q2 2017 Aug 14, 2017	BUY	N/A	9,929	9,929 $338,000

Others Institutions Holding AZN

# of Institutions

1,361

Shares Held

475M

Call Options Held

5.39M

Put Options Held

3.75M

View Full List

About ASTRAZENECA PLC

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $203B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

More about AZN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of United Capital Financial Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on United Capital Financial Advisers, LLC with notifications on news.

Account

United Capital Financial Advisers, LLC Astrazeneca PLC Transaction History